The Company’s experience in developing novel, next generation medical diagnostic technology aligns with the Wyss Diagnostics Accelerator’s mission of delivering disruptive innovation to address unmet clinical needs.
SEATTLE – June 5, 2024 – Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced that it has joined the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator.
The Wyss Institute at Harvard University is a translational research institute, developing disruptive innovation for healthcare and sustainability, powered by a multidisciplinary bioengineering community. The Wyss DxA Industrial Participant Program (Wyss DxA IPP) serves as a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem. IPP members build relationships and explore pre-competitive collaboration opportunities, connect with thought leaders and subject matter experts, identify key opportunities and challenges within the industry, and align on a vision to transform the future of diagnostic and healthcare testing. This is all driven by the DxA’s mission to accelerate the delivery of novel diagnostic technologies to patients with the goal of driving positive health care outcomes and reducing disease burden.
As a member, Know Labs will contribute experience in developing novel radiofrequency (RF) dielectric sensor technology for broader medical diagnostics applications, and specifically for applications relating to non-invasive blood glucose monitoring for diabetes management. Know Labs’ extensive patent portfolio covers more than 100 medical and non-medical applications and over 300 patents issued, pending and in-process. Know Labs joins 19 existing Wyss DxA IPP members representing a range of diagnostically relevant disciplines to accelerate the development of market solutions that solve high-value, unmet and urgent clinical needs.
“It’s an honor to participate with the Wyss Institute ecosystem and join forces with the members of the Wyss DxA IPP,” said Ron Erickson, CEO and Chairman at Know Labs. “We look forward to making contributions regarding innovation in the diabetes field and worldwide disease prevention and management more broadly. Know Labs will benefit from access to the Wyss DxA’s community and collaborators as we work to bring the first FDA-cleared non-invasive continuous glucose monitor to the marketplace and champion the need for equitable care in diabetes management.”
To learn more about Know Labs and its next generation diagnostic technology, visit the company’s website: www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.
For Know Labs Media Inquiries Contact:
Matter Health
Abby Mayo
Ph. (617) 272-0592
Know Labs, Inc. Contact:
Jordyn Hujar
Ph. (206) 629-6414